HRTS
Heart & Health ETF

Invest in Healthcare Companies Fighting Chronic Disease.

Share Price:

$34.64

April 17, 2026

Why Invest in HRTS?

High Growth Potential

Healthcare is a critical sector of the U.S. economy, and its share has been rising for generations—projected to approach one-fifth of GDP by 2030.

MedPac, 2024

Breakthrough Innovations

Global weight-loss therapy sales are projected to reach $100bn annually by the end of the decade, underscoring the scale of one major breakthrough—and the potential for more to follow.

McKinsey, 2026

Investment Expertise

HRTS is managed by a Penn-trained physician and veteran investor with more than two decades of healthcare investing experience.

Portfolio Highlights

Eli Lilly (LLY) is the developer of Mounjaro and Zepbound—among the world's most impactful medicines for type 2 diabetes and obesity—which also demonstrate meaningful cardiovascular risk reduction.

Alnylam (ALNY) is the pioneer and leader in RNA interference (RNAi) therapeutics, with approved medicines targeting rare and cardiovascular diseases including transthyretin amyloid cardiomyopathy—a frequently underdiagnosed and fatal heart condition.

Edwards Lifesciences (EW) is the global leader in transcatheter heart valve therapies, pioneering the procedure that allows patients with severe aortic stenosis to receive a new valve without open-heart surgery.

Portfolio Holdings are subject to change. Review current holdings below.

Fund Overview

Fund Details

As of April 17, 2026

Ticker

HRTS

CUSIP

87975E883

Inception Date

11/20/23

Gross Expense Ratio

0.99%

Net Expense Ratio*

0.75%

AUM

$51,627,662

Shares Outstanding

1,490,000

Number of Holdings

Primary Exchange

Nasdaq

Portfolio Manager

David K. Song, MD, PhD, CFA

*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/28/2027.

Fund Summary

The Tema Heart & Health ETF (HRTS) invests in companies advancing prevention and treatment across chronic conditions, including heart disease, diabetes, and obesity.

HRTS Overview

Summary Prospectus

Introducing HRTS

Portfolio Breakdown

Top 10 Holdings

As of April 17, 2026

Company

% of Nav

ELI LILLY & CO

9.59%

ASTRAZENECA PLC

4.90%

ROCHE HOLDING AG

4.70%

UNITEDHEALTH GROUP INC

4.44%

MERCK & CO INC

4.25%

THERMO FISHER SCIENTIFIC INC

4.21%

JOHNSON & JOHNSON

4.20%

GILEAD SCIENCES INC

3.49%

NOVARTIS AG

3.38%

REVOLUTION MEDICINES INC

3.12%

Download Holdings

Country Breakdown

United States

74.68%

Switzerland

8.08%

United Kingdom

4.90%

Denmark

4.87%

Others

7.47%

Industry Breakdown

Health Care

99.38%

Cash & Cash Equivalents

0.61%

ETF Characteristics

As of April 17, 2026

Returns on Equity

16.60%

Weighted Average Market Cap

254,048 M

Price-to-Earnings (P/E)

27.7

Price-to-Book Value (P/BV)

4.4

Price-to-Sales (P/S)

2.5

Risk Statistics

As of March 31, 2026

Versus

BETA

XBI

0.54

S&P 500

0.59

Nasdaq 100

0.43

MSCI-EAFE

0.72

MSCI Emg. Mkts.

0.50

Standard Deviation

19.30%

Performance
Distributions
Premium / Discount

Prices & Performance

As of

Mar 31, 2026

HRTS

3 months

1 Year

3 Years

5 Years

Since inception

NAV

-4.93% -4.93%

16.30% 16.30%

11.93% 11.93%

Market Price

-4.55% -4.55%

16.40% 16.40%

12.10% 12.10%

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. For most recent month-end performance, please email info@temaetfs.com. Returns for periods of less than one year are not annualized.

The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

Dec 11, 2024

Dec 12, 2024

$0.46931283

$0.14290283

Dec 10, 2025

Dec 11, 2025

$0.47290596

-0.04 -0.02 0.05 -0.04 -0.07 -0.11 0.01 0.03 -0.16 -0.1 -0.4 0.04 -0.26 -0.38 -0.55 -0.14 -0.19 0.1 -1.17 -0.39 0.04

Premium/Discount

Сhart Table

Days Traded at Nav

Days Traded at Premium

Days Traded at Discount

2023/Q4

2024/Q1

2024/Q2

2024/Q3

2024/Q4

2025/Q1

2025/Q2

2025/Q3

2025/Q4

2026/Q1

HRTS NAV / Market Price

NAV$34.65

Daily Change$0.45

Market Price$34.64

Median Bid/Ask Spread (30 Day)0.24%

Market Price Change (1D)$0.44

Premium/Discount-0.04%

As of: April 17, 2026

April-26 March-26 February-26 January-26 December-25 November-25 October-25 September-25 August-25 July-25 June-25 May-25 April-25

Full profile

Investment Partner
David K. Song, MD, PhD, CFA

David Song is the Head of Healthcare and Investment Partner at Tema ETFs. David has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton. David is a CFA charter holder.

Full profile

Using HRTS in a Portfolio

Investment Style Box

Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

portfolio chart-Jan-12-2024-05-49-21-8745-PM

HRTS ETF

Equity core

Where could a position be funded from?

Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.
Provides a balanced exposure across key technologies and company risk profiles.
Could replace a satellite or a growth-oriented position.

How to buy

*Neither Tema ETFs LLC nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.

Latest Research & Insights

Stay informed with our latest research, insights, and market analysis to make better investment decisions.

5 Questions on Healthcare with Investment Partner, Dr. David Song

Insights on the future of healthcare, innovation opportunities, and AI's role in revolutionizing the sector from investment partner, Dr. David K. Song.

Read the Full Article

Is Healthcare the Most Mispriced AI Opportunity?

Discover why healthcare, trading at a significant discount to tech and AI stocks, might be the most undervalued AI investment opportunity today.

Read the Full Article

White Paper: Healthcare’s Next Cycle is Taking Shape

An in-depth perspective on the recovery and future growth of the healthcare sector, driven by innovation and AI, as outlined in Dr David Song's latest whitepaper.

Read the Full Article

Risk Information

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com. Read the prospectus carefully before investing.

On 06/27/2025 the Tema GLP-1, Obesity & Cardiometabolic ETF was renamed Tema Heart & Health ETF. Investing involves risk including possible loss of principal. There is no guarantee the adviser’s investment strategy will be successful.

Industry Concentration Risk: Because the Fund's assets will be concentrated in an industry or group of industries, the Fund is subject to loss due to adverse occurrences that may affect that industry or group of industries.

Biotechnology Industry Risk: The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits. In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized and more volatile than companies with greater capitalizations.

Sector Focus Risk: Obesity and Cardiology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The stock prices of Obesity and Cardiology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable.

Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained. Companies in the medical equipment industry group may be affected by the expiration of patents, litigation based on product liability, industry competition, product obsolescence and regulatory approvals, among other factors.

Investing in foreign and emerging markets involves risks relating to political, economic, or regulatory conditions not associated with investments in U.S. securities and instruments. In addition, the fund is exposed to currency risk.

Because the Funds evaluate ESG factors to assess and exclude certain investments for non-financial reasons, the Funds may forego some market opportunities available to funds that do not use these ESG factors.

Tema ETFs LLC serves as the investment adviser to Tema Heart & Health ETF (the “Fund”), and Tidal Investments LLC serves as a sub adviser to the Fund. The Fund is distributed by Vigilant Distributors, LLC, which is not affiliated with Tema ETFs LLC nor Tidal Investments LLC. Check the background of Vigilant Distributors, LLC on FINRA’s BrokerCheck.

Get in Touch

HRTS Heart & Health ETF

$34.64

Why Invest in HRTS?

High Growth Potential

Breakthrough Innovations

Investment Expertise

Portfolio Highlights

Fund Overview

Fund Details

As of April 17, 2026

Fund Summary

Introducing HRTS

Portfolio Breakdown

Top 10 Holdings

As of April 17, 2026

Country Breakdown

United States

Switzerland

United Kingdom

Denmark

Others

Industry Breakdown

Health Care

Cash & Cash Equivalents

ETF Characteristics

As of April 17, 2026

Risk Statistics

As of March 31, 2026

Prices & Performance

HRTS

3 months

1 Year

3 Years

5 Years

Since inception

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

Premium/Discount

Days Traded at Nav

Days Traded at Premium

Days Traded at Discount

HRTS NAV / Market Price

Investment Partner David K. Song, MD, PhD, CFA

Using HRTS in a Portfolio

Investment Style Box

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

Where could a position be funded from?

Fund Documents

How to buy

Latest Research & Insights

5 Questions on Healthcare with Investment Partner, Dr. David Song

Is Healthcare the Most Mispriced AI Opportunity?

White Paper: Healthcare’s Next Cycle is Taking Shape

Subscribe for Updates

Risk Information

HRTS
Heart & Health ETF

Investment Partner
David K. Song, MD, PhD, CFA